The U.S. Court of Appeals for the Federal Circuit has upheld a decision previously made by a Virginia federal court that supported the U.S. Patent and Trademark Office’s refusal to grant a patent on a method related to cancer treatment. The request, filed by a unit within AbbVie, aimed to secure a patent for what was asserted to be a novel approach to administering a clinical-stage cancer therapy. This ruling indicates that both the federal judge and the Patent Office found the application lacking in elements necessary to meet the patent criteria.
Details of the Federal Circuit’s analysis of the case can be found in the Law360 article on this matter, which sheds light on the intricacies of the legal decisions made.